In the April–June 2015 edition of Corporate Disputes, Dr. Gregory Bell and Professor Iain Cockburn discuss damages in the pharmaceutical and biotech sector . To read more, click on the link below.
MFN is rewriting the launch planning playbook: Commercial and market access strategies must integrate to succeed
MFN-related uncertainty is reshaping pharmaceutical launch planning by making pricing, sequencing, and forecasting decisions more interconnected and...